ALC Stock Forecast & Price Target

Alcon is well positioned in the visioncare and surgical segments, with leading brands and a large installed base of surgical equipment. They have recently launched new products like TRYPTYR for dry eye disease, and a head-to-head clinical trial with Bausch + Lomb for their SYSTANE PRO product. Risks include potential delays in product rollouts, slower market growth, and increased competition, but the company's financials are strong and indicate potential for share gains and accelerated growth.

Alcon is facing challenges in expanding its growth and profitability due to weaker-than-expected uptake of new products and increased competition. This is resulting in growth below the 6% - 8% range and operating margins not being able to expand beyond the low-20s over a longer period of time. Additionally, costs are growing above expectations, potentially hindering the company's ability to generate strong returns for investors.